Vasso Apostolopoulos

Prof. Vasso Apostolopoulos

Victoria University
orcid

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2017 in Maturitas
Verified
Journal Article
Closed access
KMKathleen Mikkelsen
Kathleen Mikkelsen
LSLily Stojanovska
Lily Stojanovska
MPMomir Polenakovic
Momir Polenakovic
MBMarijan Bosevski
Marijan Bosevski
Vasso ApostolopoulosVasso Apostolopoulos
Vasso Apostolopoulos

1 September 2006 in Methods
Verified
Journal Article
Closed access
SXSue Xiang
Sue Xiang
ASAnja Scholzen
Anja Scholzen
GMGabriela Minigo
Gabriela Minigo
CDCassandra David
Cassandra David
Vasso ApostolopoulosVasso Apostolopoulos
Vasso Apostolopoulos
Magdalena PlebanskiMagdalena Plebanski
Magdalena Plebanski

15 January 2021 in Molecules
Verified
Journal Article
Open access
PDF file
Vasso ApostolopoulosVasso Apostolopoulos
Vasso Apostolopoulos
BJBojarska Joanna
Bojarska Joanna
Tsun-Thai ChaiTsun-Thai Chai
Tsun-Thai Chai
Sherif M. ElnagdySherif M. Elnagdy
Sherif M. Elnagdy
KKKrzysztof Kaczmarek
Krzysztof Kaczmarek
Istvan TothIstvan Toth
Istvan Toth
Peptides are fragments of proteins that carry out biological functions. They act as signaling entities via all domains of life and interfere with protein-protein interactions, which are indispensable in bio-processes. Short peptides include fundamental molecular information for a prelude to the symphony of life. They have aroused considerable interest due to their unique features and great promise in innovative bio-therapies. This work focusing on the current state-of-the-art short peptide-based therapeutical developments is the first global review written by researchers from all continents, as a celebration of 100 years of peptide therapeutics since the commencement of insulin therapy in the 1920s. Peptide “drugs” initially played only the role of hormone analogs to balance disorders. Nowadays, they achieve numerous biomedical tasks, can cross membranes, or reach intracellular targets. The role of peptides in bio-processes can hardly be mimicked by other chemical substances. The article is divided into independent sections, which are related to either the progress in short peptide-based theranostics or the problems posing challenge to bio-medicine. In particular, the SWOT analysis of short peptides, their relevance in therapies of diverse diseases, improvements in (bio)synthesis platforms, advanced nano-supramolecular technologies, aptamers, altered peptide ligands and in silico methodologies to overcome peptide limitations, modern smart bio-functional materials, vaccines, and drug/gene-targeted delivery systems are discussed.

29 March 2021 in Cancers
Verified
Journal Article
Open access
PDF file
KSKristen Mc Sweeney
Kristen Mc Sweeney
LGLaura Kate Gadanec
Laura Kate Gadanec
TQTawar Qaradakhi
Tawar Qaradakhi
Benazir AliBenazir Ali
Benazir Ali
AZAnthony Zulli
Anthony Zulli
Vasso ApostolopoulosVasso Apostolopoulos
Vasso Apostolopoulos
Administration of the chemotherapeutic agent cisplatin leads to acute kidney injury (AKI). Cisplatin-induced AKI (CIAKI) has a complex pathophysiological map, which has been linked to cellular uptake and efflux, apoptosis, vascular injury, oxidative and endoplasmic reticulum stress, and inflammation. Despite research efforts, pharmaceutical interventions, and clinical trials spanning over several decades, a consistent and stable pharmacological treatment option to reduce AKI in patients receiving cisplatin remains unavailable. This has been predominately linked to the incomplete understanding of CIAKI pathophysiology and molecular mechanisms involved. Herein, we detail the extensively known pathophysiology of cisplatin-induced nephrotoxicity that manifests and the variety of pharmacological and genetic alteration studies that target them.

7 July 2017 in Brain Sciences
Verified
Journal Article
Open access
PDF file
NDNarges Dargahi
Narges Dargahi
MKMaria Katsara
Maria Katsara
Theodore TseliosTheodore Tselios
Theodore Tselios
MAMaria-Eleni Androutsou
Maria-Eleni Androutsou
MCMaximilian de Courten
Maximilian de Courten
Vasso ApostolopoulosVasso Apostolopoulos
Vasso Apostolopoulos
The treatment of multiple sclerosis (MS) has changed over the last 20 years. All immunotherapeutic drugs target relapsing remitting MS (RRMS) and it still remains a medical challenge in MS to develop a treatment for progressive forms. The most common injectable disease-modifying therapies in RRMS include β-interferons 1a or 1b and glatiramer acetate. However, one of the major challenges of injectable disease-modifying therapies has been poor treatment adherence with approximately 50% of patients discontinuing the therapy within the first year. Herein, we go back to the basics to understand the immunopathophysiology of MS to gain insights in the development of new improved drug treatments. We present current disease-modifying therapies (interferons, glatiramer acetate, dimethyl fumarate, teriflunomide, fingolimod, mitoxantrone), humanized monoclonal antibodies (natalizumab, ofatumumab, ocrelizumab, alemtuzumab, daclizumab) and emerging immune modulating approaches (stem cells, DNA vaccines, nanoparticles, altered peptide ligands) for the treatment of MS.

25 February 2021 in Nutrients
Verified
Journal Article
Open access
PDF file
HSHira Shakoor
Hira Shakoor
Jack FeehanJack Feehan
Jack Feehan
Vasso ApostolopoulosVasso Apostolopoulos
Vasso Apostolopoulos
CPcarine platat
carine platat
Ayesha Al DhaheriAyesha Al Dhaheri
Ayesha Al Dhaheri
Lily StojanovskaLily Stojanovska
Lily Stojanovska
Functional and nutraceutical foods provide an alternative way to improve immune function to aid in the management of various diseases. Traditionally, many medicinal products have been derived from natural compounds with healing properties. With the development of research into nutraceuticals, it is becoming apparent that many of the beneficial properties of these compounds are at least partly due to the presence of polyphenols. There is evidence that dietary polyphenols can influence dendritic cells, have an immunomodulatory effect on macrophages, increase proliferation of B cells, T cells and suppress Type 1 T helper (Th1), Th2, Th17 and Th9 cells. Polyphenols reduce inflammation by suppressing the pro-inflammatory cytokines in inflammatory bowel disease by inducing Treg cells in the intestine, inhibition of tumor necrosis factor-alpha (TNF-α) and induction of apoptosis, decreasing DNA damage. Polyphenols have a potential role in prevention/treatment of auto-immune diseases like type 1 diabetes, rheumatoid arthritis and multiple sclerosis by regulating signaling pathways, suppressing inflammation and limiting demyelination. In addition, polyphenols cause immunomodulatory effects against allergic reaction and autoimmune disease by inhibition of autoimmune T cell proliferation and downregulation of pro-inflammatory cytokines (interleukin-6 (IL-6), IL-1, interferon-γ (IFN-γ)). Herein, we summarize the immunomodulatory effects of polyphenols and the underlying mechanisms involved in the stimulation of immune responses.